SCHEMBL3377228

SCHEMBL3377228

O=C(Nc1ccccc1)c1cccc(N(Cc2ccccc2)S(=O)(=O)c2ccccc2)c1

nearest known ligand 0.74

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.74
LMNA P02545 6/20 0.74
ALDH1A1 P00352 2/20 0.62
GAA P10253 1/20 0.60
HTT P42858 1/20 0.60
KMT2A Q03164 4/20 0.57
KDM4E B2RXH2 2/20 0.57
MEN1 O00255 3/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
TSHR P16473 1/20 0.57
PTGES O14684 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3377793 0.91 MAPT (0.64) MAPTLMNAALDH1A1GAAHTT
SCHEMBL3378728 0.91 MAPT (0.70) MAPTLMNAALDH1A1GAAHTT
SCHEMBL3380407 0.87 LMNA (0.64) MAPTLMNAALDH1A1GAAHTT
SCHEMBL2186493 0.86 ALDH1A1 (0.62) MAPTLMNAALDH1A1GAAHTT
SCHEMBL2189346 0.85 LMNA (0.85) MAPTLMNAALDH1A1GAAHTT
SCHEMBL3376241 0.85 LMNA (0.61) MAPTLMNAALDH1A1GAAHTT
SCHEMBL3377009 0.84 MAPT (0.61) MAPTLMNAALDH1A1GAAHTT
SCHEMBL3376225 0.84 MAPT (0.61) MAPTLMNAALDH1A1GAAHTT
SCHEMBL3375719 0.84 LMNA (0.60) MAPTLMNAALDH1A1GAAHTT
SCHEMBL302225 0.84 LMNA (0.60) MAPTLMNAALDH1A1GAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342177-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-02-15 EP claimed
US-9447033-B2 Potassium channel blockers JAPAN TOBACCO INC. (JP) 2016-09-20 US claimed
US-20150259282-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2015-09-17 US claimed
US-20100087428-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
EP-2342177-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-02-15 EP disclosed
US-9447033-B2 Potassium channel blockers JAPAN TOBACCO INC. (JP) 2016-09-20 US disclosed
US-20150259282-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2015-09-17 US disclosed
US-9073834-B2 Potassium channel blockers XENTION LIMITED (GB) 2015-07-07 US disclosed
US-8673901-B2 Potassium channel blockers XENTION LIMITED (GB) 2014-03-18 US disclosed
US-20100087428-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087428-A1 Novel Potassium Channel Blockers HCN4, SCN2B, KCNH2 MAPT 4874/4885LMNA 2145/4885ALDH1A1 3795/4885
US-20150259282-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 MAPT 2884/4885LMNA 1619/4885ALDH1A1 1360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.